Company Encyclopedia
View More
name
LB Pharmaceuticals
LBRX.US
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
4.514 T
LBRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LB Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Kaya Kamlesh Pai Panandiker

    LB Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. SEC, listing Kaya Kamlesh Pai Panandiker as the beneficial owner and Chief Commercial Officer. This filing is accessible via EDGAR, the SEC's system. The information was published on November 18, 2025, and is for informational purposes only, not financial or legal advice.

    Reuters·
    US
    LBRX
    +2.61%
    Reuters·
    US
    LBRX
    +2.61%

    LB Pharma, Celldex hire commercial heads as launch plans ramp up

    LB Pharmaceuticals and Celldex have appointed new chief commercial officers to prepare for potential drug launches. LB hired Kaya Pai Panandiker, leveraging her experience in brain disease drug launches, after raising $285 million through an IPO. Celldex appointed Teri Lawver, following the retirement of Richard Wright, to prepare for the potential launch of barzolvolimab for a skin condition.

    Fiercepharma·
    US
    CLDX
    +6.44%
    US
    LBRX
    +2.61%
    Fiercepharma·
    US
    CLDX
    +6.44%
    US
    LBRX
    +2.61%

    LB Pharmaceuticals Expands One Penn Plaza Lease with Additional 4,634 Square Feet

    LB Pharmaceuticals Inc. has amended its lease with One Penn Plaza LLC to include an additional 4,634 square feet on the 10th floor, effective until March 31, 2032. The expansion premises will be delivered by July 1, 2026, with an initial annual rent of $430,962, increasing to $477,302 after three years. A rent abatement applies for the first 150 days post-delivery.

    Reuters·
    US
    LBRX
    +2.61%
    Reuters·
    US
    LBRX
    +2.61%

    LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

    NEW YORK, Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( Nasdaq: LBRX ) today announced that it has granted to James Rawls, the new Senior Vice President of Regulatory Affairs of LB Pharmaceuticals, an equity award outside of, but subject ...

    GlobeNewswire·
    US
    LBRX
    +2.61%
    GlobeNewswire·
    US
    LBRX
    +2.61%

    LB PHARMACEUTICALS INC SEC 10-Q Report

    LB Pharmaceuticals Inc has released its Form 10-Q report for Q3 2025, showing significant financial improvements. The total operating loss decreased to $(5.2) million from $(16.1) million year-over-year. The net loss also improved to $(3.6) million from $(14.2) million. The company is focused on developing its lead product candidate, LB-102, with plans for a Phase 3 trial in Q1 2026. Future outlook indicates sufficient funds to support operations until Q2 2028, with topline data expected in 2027 and 2028 for various trials.

    TradingView·
    US
    LBRX
    +2.61%
    TradingView·
    US
    LBRX
    +2.61%
    © 2025 Longbridge｜Disclaimer